Bepotastine/corticosteroid intranasal - ISTA Pharmaceuticals

Drug Profile

Bepotastine/corticosteroid intranasal - ISTA Pharmaceuticals

Alternative Names: Beposone; Bepotastine besilate/steroid; Steroid/bepotastine intranasal - ISTA Pharmaceuticals

Latest Information Update: 19 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ISTA Pharmaceuticals
  • Class Antiallergics; Antihistamines; Corticosteroids; Piperidines; Pyridines; Small molecules; Steroids
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
  • 01 May 2012 Final efficacy and adverse events data from a phase II trial in Seasonal allergic rhinitis released by ISTA Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top